{
    "id": 9053,
    "name": "bladder carcinoma in situ",
    "source": "DOID",
    "definition": "An in situ carcinoma that is located_in the bladder. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647140/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:9053",
    "evidence": [
        {
            "id": 10666,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial that supported FDA approval, treatment with Valstar (valrubicin) resulted in complete response in 21% (19/90) of patients with bacillus Calmette-Guerin (BCG)-refractory bladder carcinoma in situ (PMID: 10687972).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1056,
                "therapyName": "Valrubicin",
                "synonyms": null
            },
            "indication": {
                "id": 9053,
                "name": "bladder carcinoma in situ",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8728,
                    "pubMedId": 10687972,
                    "title": "Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10687972"
                },
                {
                    "id": 15650,
                    "pubMedId": null,
                    "title": "Valstar (valrubicin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020892"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12081,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial supporting FDA approval, TICE BCG solution (BCG solution) treatment resulted in an estimated 2 year disease-free survival rate of 57% (109/191) in patients with bladder carcinoma in situ (PMID: 21224104).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4455,
                "therapyName": "BCG solution",
                "synonyms": null
            },
            "indication": {
                "id": 9053,
                "name": "bladder carcinoma in situ",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10016,
                    "pubMedId": 21224104,
                    "title": "Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224104"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12379,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Oportuzumab monatox (VB4-845) was well-tolerated and resulted in complete response in 44% (20/45) of patients with bladder carcinoma in situ refractory to bacillus Calmette-Guerin (BCG) therapy (PMID: 22998907; NCT00462488)",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6290,
                "therapyName": "Oportuzumab monatox",
                "synonyms": null
            },
            "indication": {
                "id": 9053,
                "name": "bladder carcinoma in situ",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10356,
                    "pubMedId": 22998907,
                    "title": "A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Gu\u00e9rin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22998907"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19723,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (KEYNOTE-057) that supported FDA approval, Keytruda (pembrolizumab) treatment demonstrated safety and efficacy, resulted in a 3-month complete response rate of 40.2% (41/102), with a median duration of follow-up of 15.8 months in patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors who are unable or refuse to undergo cystectomy (J Clin Onc 37, no. 15_suppl (May 20, 2019) 4530-4530; NCT02625961).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9053,
                "name": "bladder carcinoma in situ",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                },
                {
                    "id": 17526,
                    "pubMedId": null,
                    "title": "Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non\u2013muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG): Updated follow-up from KEYNOTE-057.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4530"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03091660",
            "title": "Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5478,
                    "therapyName": "BCG Tokyo-172 Strain Solution",
                    "synonyms": null
                },
                {
                    "id": 4455,
                    "therapyName": "BCG solution",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03106610",
            "title": "Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        }
    ]
}